X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders
Key Highlights
- ➤X4 sets October 29 Investor Day focused on mavorixafor in chronic neutropenia
- ➤Phase 3 4WARD trial status will be reviewed at the Investor Day
- ➤Planned Phase 2 trial will test reducing G-CSF doses while maintaining normal neutrophil counts
- ➤X4 will present mavorixafor’s potential commercial opportunity in chronic neutropenia
- ➤FDA granted mavorixafor Fast Track designation for chronic neutropenia
BOSTON, Oct. 09, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that the Company will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.
The Investor Day will feature discussions with X4 Pharmaceuticals management and key opinion leaders on mavorixafor as a potential treatment for chronic neutropenia. Management will review the current status of the Phase 3 4WARD clinical trial and will outline a planned Phase 2 clinical trial of mavorixafor in combination with granulocyte colony-stimulating factor (G-CSF), designed to assess patients' ability to titrate down their G-CSF dose while maintaining normal neutrophil counts.
Get started
Create a free account to read the full story.